Strong Hepatitis C Cocktail Contenders

[Guest guest]

Strong Hepatitis C Cocktail Contenders

Two of Gilead's investigational drugs, GS 9190 and GS 9256, showed high HCV viral suppression rates - especially when combined with ribavirin and pegylated interferon.

Gilead's Investigational Hepatitis C Compounds GS 9190 and GS 9256 in Combination with Standard of Care Therapies Achieve Substantial Viral Suppression in Phase II Study

-- Compounds Among the Company's Seven HCV Pipeline Candidates Spanning Six Therapeutic Classes --

BOSTON, Oct 30, 2010 (BUSINESS WIRE) -- Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.

Continue reading this entire article:http://www.marketwatch.com/story/gileads-investigational-hepatitis-c-compounds-gs-9190-and-gs-9256-in-combination-with-standard-of-care-therapies-achieve-substantial-viral-suppression-in-phase-ii-study-2010-10-30?reflink=MW_news_stmp

http://www.hepatitis-central.com/mt/archives/2010/11/strong_hepatiti.html